News for Aileron Therapeutics, Inc. (ALRN)

PR NewswireAUSTIN, Texas, May 15, 2025 RENEW Phase 2 trial evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IP

PR NewswireAUSTIN, Texas, Jan. 10, 2025 Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmon

Aileron Therapeutics, Inc. (ALRN) experienced a significant stock drop of 7.55%, trading at $1.96 per share. The trading volume reached 84,710 shares with a tur

Aileron Therapeutics, Inc. (ALRN), a clinical-stage biopharmaceutical company, experienced a significant stock price increase of 5.27%, reaching $2.70 per share

Aileron Therapeutics, Inc. (ALRN) recently experienced a significant stock drop of 5.26%, bringing its price to $3.60 per share. The trading volume reached 40,4

Aileron Therapeutics, Inc. (ALRN) experienced a notable stock movement with a 6.19% decline in its share price. The shares are now trading at $3.87 with a tradi

Advancium explores ALRN-6924 for pediatric eye cancer treatment

On October 25, 2024, KCK LTD. (Trades, Portfolio) executed a significant transaction by reducing its stake in NeuroPace Inc (NPCE), a key player in the medical

On October 22, 2024, KCK LTD. (Trades, Portfolio), a prominent investment firm, executed a significant transaction involving the shares of NeuroPace Inc (NPCE).

Aileron Therapeutics, Inc. (ALRN), a clinical-stage biopharmaceutical company, saw its stock price rise by 5.04%. The stock is currently priced at $3.75, with a

On October 21, 2024, KCK LTD. (Trades, Portfolio) executed a significant transaction involving the sale of 8,598 shares of NeuroPace Inc (NPCE), a key player in

Aileron Therapeutics, Inc. (ALRN) experienced a significant stock drop of 5.15%, with shares priced at $3.46 and a trading volume of 31,420 shares. The stock's

Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter financial results. Quanex Building Products shares fell 10.7% to $30.95 on Friday.

Shares of Getaround, Inc. (NYSE: GETR) rose sharply in pre-market trading after the company reported a year-over-year increase in third-quarter financial results.

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.

/PRNewswire/ -- The "Constrained Peptide Drugs Market - A Global and Regional Analysis: Focus on Peptide Type, Product, and Region-Wise Analysis - Analysis and...

GuruFocus Article or News written by insider and the topic is about:

Read Research Analysts’ Downgrades for May 31st (ADVM, AGIL, AGRO, AIRYY, AKA, ALRN, AMPL, AMTB, APLT, AREC) at ETF Daily News

GuruFocus Article or News written by insider and the topic is about: